Eli Lilly and Company has announced the launch of Ramiven (abemaciclib), following approval from the DCGI (India) + endocrine therapy for adjuvant treatment in HR-positive, HER2 negative early breast cancer
Eli Lilly and Company has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2(HER2) negative, node-positive Early Breast Cancer (EBC) at high risk of recurrence
CDK 4/6 inhibitors are a class of medicines used to treat certain types of metastatic breast cancers. In India, over 50,000 patients are diagnosed with HR+/HER2- early breast cancer (EBC) every year. Close to 30 per cent of EBC patients with high-risk clinical or pathological features experience recurrence or metastasis despite receiving standard therapy.
Ramiven is already approved for the treatment of certain types of HR+ HER2- advanced or metastatic breast cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins